Chugai Pharmaceutical Co., Ltd. (CUP0) - Total Assets
Based on the latest financial reports, Chugai Pharmaceutical Co., Ltd. (CUP0) holds total assets worth €2.47 Trillion EUR as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chugai Pharmaceutical Co., Ltd. - Total Assets Trend (2021–2025)
This chart illustrates how Chugai Pharmaceutical Co., Ltd.'s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chugai Pharmaceutical Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Chugai Pharmaceutical Co., Ltd.'s total assets of €2.47 Trillion consist of 70.5% current assets and 29.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.3% |
| Accounts Receivable | €442.88 Billion | 17.9% |
| Inventory | €276.85 Billion | 11.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €54.54 Billion | 2.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Chugai Pharmaceutical Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chugai Pharmaceutical Co., Ltd.'s current assets represent 70.5% of total assets in 2025, an increase from 69.1% in 2021.
- Cash Position: Cash and equivalents constituted 17.3% of total assets in 2025, down from 17.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 17.9% of total assets.
Chugai Pharmaceutical Co., Ltd. Competitors by Total Assets
Key competitors of Chugai Pharmaceutical Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF115.49 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Chugai Pharmaceutical Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.23 | 5.09 | 5.09 |
| Quick Ratio | 3.56 | 4.17 | 4.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.33 Trillion | €1.19 Trillion | €1.19 Trillion |
Chugai Pharmaceutical Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Chugai Pharmaceutical Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.12 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 11.8% |
| Total Assets | €2.47 Trillion |
| Market Capitalization | $76.91 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Chugai Pharmaceutical Co., Ltd.'s assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Chugai Pharmaceutical Co., Ltd.'s assets grew by 11.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chugai Pharmaceutical Co., Ltd. (2021–2025)
The table below shows the annual total assets of Chugai Pharmaceutical Co., Ltd. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.47 Trillion | +11.78% |
| 2024-12-31 | €2.21 Trillion | +14.27% |
| 2023-12-31 | €1.93 Trillion | +3.36% |
| 2022-12-31 | €1.87 Trillion | +21.52% |
| 2021-12-31 | €1.54 Trillion | -- |
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal … Read more